HIF-2α inhibition using PT2385 significantly reduced tumor weight, VEGF production, vessel density, and whole tumor Mrc1 expression while increasing pericyte-coated vessels in subcutaneous LLC tumors [97], though Lu et al. reported increased LLC tumor foci in lungs of myeloid HIF-2α deficient mice using an extravasation model [101]. The gene discussed is VEGFA; the disease is neoplasm.